What is Zepbound?
Zepbound is Eli Lilly's brand tirzepatide, FDA-approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and exercise. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It comes as a weekly injection in pens and single-dose vials. Mounjaro is the same medication approved for type 2 diabetes.
Who offers brand access right now
| Brand Picture | Right Now |
|---|---|
| Providers with brand tirzepatide plans | 24 of 73 providers |
| Median monthly, lowest-priced dose | $381 |
| Full range, all doses | $20 to $1828 |
| Pricing last verified | 2026-07-08 |
These plans cover brand tirzepatide access as providers publish it, Zepbound or Mounjaro, with the all-in monthly total including required fees. Brand access comes in two shapes, and the range reflects both: at the low end are plans priced as a visit membership, with the medication billed separately through insurance or the pharmacy, while plans that include the medication in the price sit higher. The comparison list shows every plan with its price and state availability.
Brand cost by dose
Brand plans are priced by dose like the label's own tiers. Each provider counts once per dose here, at its lowest all-in monthly price for that dose.
| Weekly Dose | Providers | Median Monthly |
|---|---|---|
| 2.5 mg | 24 | $423 |
| 5 mg | 23 | $464 |
| 7.5 mg | 23 | $508 |
| 10 mg | 23 | $508 |
| 12.5 mg | 23 | $508 |
| 15 mg | 23 | $514 |
Ways to get Zepbound
- Telehealth programs: the providers tracked here bundle the prescription visit with brand fulfillment, and their plans appear in the directory with all-in pricing.
- LillyDirect: Lilly sells Zepbound single-dose vials directly at published self-pay prices, with the prescription written by your own prescriber or through its telehealth partners.
- Insurance and Medicare: coverage varies by plan. From July 2026, the Medicare GLP-1 Bridge program covers Zepbound for eligible Part D patients at $50 a month, detailed in our Medicare Bridge article.
Zepbound and compounded tirzepatide
Compounded plans are a pricing alternative to the brand versions, intended to contain the same active ingredient, though compounded versions are not FDA-approved or verified as equivalent. Both paths appear side by side in the directory.
This page is a general reference, not medical advice. Whether Zepbound fits your situation, and the dose, is a decision for you and a licensed prescriber, guided by the FDA label.
Sources: the FDA-approved Zepbound label and Eli Lilly's published program details, and each provider's own published pages, re-verified on a rolling schedule. Price figures are computed live from the same verified data as the comparison tool, most recently confirmed on the date shown above.